| Characteristic |
Overall (N=50) |
RVD (N=12) |
Control (N=38) |
p-value |
| Age (Years) |
67 ± 11.9 |
73 ± 8.4 |
62.6 ± 13.3 |
p<0.01 |
| Male sex-no. (%) |
38 (76) |
9 (75) |
29 (76) |
0.92 |
| ACS no (%) |
50 (100) |
12 (100) |
38 (100) |
0.13 |
| History of CIHD-no. (%) |
21 (42) |
6 (50) |
15 (40) |
0.14 |
| Hypertension-no. (%) |
45 (90) |
11 (92) |
34 (89) |
0.83 |
| Diabetes mellitus-no (%) |
19 (38) |
7 (58) |
12 (32) |
0.96 |
| Active Smokers-no. (%) |
7 (14) |
0 (0) |
7 (18) |
p<0.05 |
| Hypercholesterolemia-no. (%) |
28 (56) |
5 (42) |
23 (61) |
0.25 |
| Adipositas per magna-no. (%) |
15 (30) |
4 (33) |
11 (29) |
0.81 |
| Bare metal stents (%) |
29 (58) |
10 (83) |
19 (50) |
0.2 |
| Drug eluting stents (%) |
17 (34) |
2 (17) |
15 (40) |
0.31 |
| Right coronary artery as culprit lesion (%) |
23 (46) |
9 (75) |
14 (37) |
p<0.05 |
| Medications in use |
|
| Aspirin-no. (%) |
50 (100) |
12 (100) |
38 (100) |
0.18 |
| Clopidogrel-no. (%) |
50 (100) |
12 (100) |
38 (100) |
- |
| GpIIbIIIa-Inhibitor-no. (%) |
6 (12) |
2 (17) |
4 (11) |
0.57 |
| ACE-Inhibitors no. (%) |
38 (72) |
9 (75) |
29 (76) |
0.92 |
| CSE-Inhibitoren no. (%) |
44 (88) |
11 (92) |
33 (86) |
0.16 |
| Beta-Blockers no. (%) |
43 (86) |
10 (83) |
33 (86) |
0.76 |
| Heparin (%) |
50 (100) |
12 (100) |
38 (100) |
p<0.04 |
|
